Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout ⦠Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. According the Bloomberg News, Bristol-Myers Squibb (NYS: BMY) made an unsolicited offer to buy Amylin Pharmaceuticals (NAS: AMLN) for $22 per share. (Dealreporter) . What: Shares of Amylin Pharmaceuticals (Nasdaq: AMLN) soared a staggering 46% Wednesday on news that the diabetes-drug maker recently ⦠On March 27, Bloomberg News reported that Amylin had spurned a $3.5 billion takeover offer from Bristol-Myers. Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. Amylin Pharmaceuticals shares rose as much as 51% on Wednesday on reports that the company rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb. Amylin is playing hard to get. Investors are eating it ⦠According the Bloomberg News, Bristol-Myers Squibb (NYSE: BMY) made an unsolicited offer to buy Amylin Pharmaceuticals (Nasdaq: AMLN) for $22 per share. Eli Lilly (NYSE:LLY) has approached Amylin Pharmaceuticals (AMLN) with a buyout offer, sources say. Shares of Amylin Pharmaceuticals Inc. jumped Wednesday on a report the diabetes drugmaker recently turned down a buyout offer from Bristol-Myers ⦠Speculation that Amylin would be a buyout ⦠Icahn, who holds an almost 9% stake in the company, was irate after an offer of $22 per share may or may not . Amylin Attacked By Carl Icahn Over Buyout Secrecy. . It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals⦠Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) was under attack today from Carl Icahn over the board of that company's refusal to comment on rumors of a rejected takeover offer. Diabetes-drug specialist Amylin Pharmaceuticals (Nasdaq: AMLN) watched its stock shoot sky high after reports that the company had rejected a $3.5 billion buyout ⦠.
Mt News Cloppenburg Blaulicht,
Die Eulen Ludwigshafen Trikot,
Hummel Stadil High Weiss,
Nachrichten - Niedersachsen,
Fisher Price Xylophone Song Book Pdf,
Preise Jungbullen Schlachtgewicht,
Neue Kommentare